Randy Blakely, Ph.D.

Executive Director, FAU Brain Institute & Professor, Biomedical Science

  • Boca Raton FL UNITED STATES
  • FAU Brain Institute

Randy Blakely is an expert in molecular neuroscience, focusing on how diseases and drugs impact the function of brain synapses and circuits.

Contact

Multimedia

Social

Biography

Randy D. Blakely, a native of Columbus, Georgia, received his B.A. in philosophy summa cum laude from Emory University, followed by a Ph.D. in neuroscience from the Johns Hopkins School of Medicine, where he pursued studies of brain peptides with Joseph T. Coyle. Following his graduate work, Blakely pursued postdoctoral training at the Yale/HHMI Center for Molecular Neuroscience with Susan Amara, research that identified the genes encoding targets of widely used antidepressant medications and psychostimulants, including cocaine and amphetamines. As an independent investigator (Emory University, 1990-1995; Vanderbilt University, Allan D. Bass Chair, 1995-2016, Florida Atlantic University, 2016-present), Blakely has pursued studies of the genetics, structure, regulation and pathophysiology of synaptic transporters, work that appears in more than 300 research articles and scholarly reviews. In recent years, his work has focused on the identification of transporter mutations that alter neurotransmitter inactivation and/or drug recognition, leading to the generation of animal models of multiple neuropsychiatric disorders such as autism, OCD, ADHD and major depression. A committed mentor to junior scientists, Blakely has trained nearly 100 undergraduate, Masters, Ph.D. and M.D. students through his laboratory, as well as nearly 40 post-doctoral fellows, many of hold independent, leadership positions in academia or industry.

Areas of Expertise

Medications
Brain
Neuroscience
Brain Disease
Synapse

Accomplishments

Daniel Efron Award

ACNP

MERIT Award

NIMH

Distinguished Investigator Award

Brain and Behavioral Research Foundation

Show All +

Education

Johns Hopkins School of Medicine

Ph.D.

Emory University

B.A.

Selected Media Appearances

Randy Blakely Receives 2022 SfN Science Educator Award

Dana Foundation  online

2022-11-14

Each year, the Society for Neuroscience recognizes outstanding neuroscientists who have strongly added to public education and awareness about the field. The Dana Foundation sponsors these awards. This year’s award was presented to Randy Blakely, Ph.D., Florida Atlantic University Stiles-Nicholson Brain Institute.

View More

Rare Human Gene Variant in ADHD, Autism Exposes Fundamental Sex Differences

Neuroscience News  online

2022-09-21

The new research published in the journal Molecular Psychiatry and led by Randy Blakely, Ph.D., professor of biomedical science in FAU’s Schmidt College of Medicine and executive director of the FAU Stiles-Nicholson Brain Institute, provides new insight into how sex determines the mechanisms by which distinct synapses monitor and regulate dopamine signaling.

View More

The scientific reason it feels so good to come home after a long day

Ladders  online

2020-11-17

“Our data provide clear evidence of a biochemical foundation for the reinforcing properties of home cage return. This simple environmental manipulation can provide a minimally-invasive approach to peel away aspects of reward circuitry connected to natural reinforcers – one that is critical to an animal’s survival,” says senior study author Randy Blakely, Ph.D., executive director of FAU’s Brain Institute and a professor of biomedical science in FAU’s Schmidt College of Medicine, in a release. [...]

View More

Show All +

Selected Articles

Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice

Neuropsychopharmacology

Randy Blakely et al.

2018

Dopamine (DA) signaling dysfunction is believed to contribute to multiple neuropsychiatric disorders including attention-deficit/hyperactivity disorder (ADHD). The rare DA transporter (DAT) coding substitution Ala559Val found in subjects with ADHD, bipolar disorder and autism, promotes anomalous DA efflux in vitro and, in DAT Val559 mice, leads to increased reactivity to imminent handling, waiting impulsivity, and enhanced motivation for reward. Here, we report that, in contrast to amphetamine and methylphenidate, which induce significant locomotor activation, cocaine administration to these mice elicits no locomotor effects, despite retention of conditioned place preference (CPP). Additionally, cocaine fails to elevate extracellular DA. Given that amphetamine and methylphenidate, unlike cocaine, lack high-affinity interactions with the serotonin (5-HT) transporter (SERT), we hypothesized that the lack of cocaine-induced hyperlocomotion in DAT Val559 mice arises from SERT blockade and augmented 5-HT signaling relative to cocaine actions on wildtype animals. Consistent with this idea, the SERT blocker fluoxetine abolished methylphenidate-induced locomotor activity in DAT Val559 mice, mimicking the effects seen with cocaine. Additionally, a cocaine analog (RTI-113) with greater selectivity for DAT over SERT retains locomotor activation in DAT Val559 mice. Furthermore, genetic elimination of high-affinity cocaine interactions at SERT in DAT Val559 mice, or specific inhibition of 5-HT2C receptors in these animals, restored cocaine-induced locomotion, but did not restore cocaine-induced elevations of extracellular DA. Our findings reveal a significant serotonergic plasticity arising in the DAT Val559 model that involves enhanced 5-HT2C signaling, acting independently of striatal DA release, capable of suppressing the activity of cocaine-sensitive motor circuits.

View more

Cell-Type-Specific Interleukin 1 Receptor 1 Signaling in the Brain Regulates Distinct Neuroimmune Activities

Immunity

Randy Blakely et al.

2019

Interleukin-1 (IL-1) signaling is important for multiple potentially pathogenic processes in the central nervous system (CNS), but the cell-type-specific roles of IL-1 signaling are unclear. We used a genetic knockin reporter system in mice to track and reciprocally delete or express IL-1 receptor 1 (IL-1R1) in specific cell types, including endothelial cells, ventricular cells, peripheral myeloid cells, microglia, astrocytes, and neurons. We found that endothelial IL-1R1 was necessary and sufficient for mediating sickness behavior and drove leukocyte recruitment to the CNS and impaired neurogenesis, whereas ventricular IL-1R1 was critical for monocyte recruitment to the CNS. Although microglia did not express IL-1R1, IL-1 stimulation of endothelial cells led to the induction of IL-1 in microglia. Together, these findings describe the structure and functions of the brain’s IL-1R1-expressing system and lay a foundation for the dissection and identification of IL-1R1 signaling pathways in the pathogenesis of CNS diseases.

View more

Human Serotonin Transporter Coding Variation Establishes Conformational Bias with Functional Consequences

ACS Chemical Neuroscience

Randy Blakely

2019

The antidepressant-sensitive serotonin (5-HT) transporter (SERT) dictates rapid, high-affinity clearance of the neurotransmitter in both the brain and periphery. In a study of families with multiple individuals diagnosed with autism spectrum disorder (ASD), we previously identified several, rare, missense coding variants that impart elevated 5-HT transport activity, relative to wild-type SERT, upon heterologous expression as well as in ASD subject lymphoblasts. The most common of these variants, SERT Ala56, located in the transporter’s cytosolic N-terminus, has been found to confer in transgenic mice hyperserotonemia, an ASD-associated biochemical trait, an elevated brain 5-HT clearance rate, and ASD-aligned behavioral changes. Hyperfunction of SERT Ala56 has been ascribed to a change in 5-HT KM, though the physical basis of this change has yet to be elucidated. Through assessments of fluorescence resonance energy transfer (FRET) between cytosolic N- and C-termini, sensitivity to methanethiosulfonates, and capacity for N-terminal tryptic digestion, we obtain evidence for mutation-induced conformational changes that support an open-outward 5-HT binding conformation in vitro and in vivo. Aspects of these findings were also evident with another naturally occurring C-terminal SERT coding variant identified in our ASD study, Asn605. We conclude that biased conformations of surface resident transporters that can impact transporter function and regulation are an unappreciated consequence of heritable and disease-associated SERT coding variation.

View more

Show All +